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Purpose:  The  pathophysiology  of  acute  coronary  syndromes  (ACS)  after  noncardiac  surgery  is  not  estab-
lished yet.  Thrombosis  over  a vulnerable  plaque  or decreased  oxygen  supply  secondary  to  anemia  or
hypotension  may  be involved.  The  purpose  of  this  study  was  to investigate  the pathophysiology  of  ACS
complicating  noncardiac  surgery.
Methods:  Clinical  and  angiographic  data  were  prospectively  recorded  into  a database  for  120  consecutive
patients  that  had  an  ACS after  noncardiac  surgery  (PACS),  for 120 patients  with  spontaneous  ACS  (SACS),
and 240  patients  with  stable  coronary  artery  disease  (CAD).  Coronary  lesions  with obstructions  greater
than  50%  were  classiﬁed  based  on  two criteria:  Ambrose’s  classiﬁcation  and  complex  morphology.  The
presence  of  Ambrose’s  type  II or complex  lesions  were  compared  between  the  three  groups.
Results:  We  analyzed  1470  lesions  in  480 patients.  In  PACS  group,  45% of patients  had  Ambrose’s  type II
lesions  vs.  56.7%  in  SACS  group  and  16.4%  in  stable  CAD  group  (P < 0.001).  Both  PACS  and  SACS  patients
had  more  complex  lesions  than patients  in  stable  CAD  group  (56.7%  vs.  79.2%  vs.  31.8%,  respectively;
P  <  0.001).  Overall,  the  independent  predictors  of plaque  rupture  were  being  in  the  group  PACS  (P <  0.001,
OR 2.86;  CI,  1.82–4.52  for complex  lesions  and P <  0.001,  OR  3.43;  CI, 2.1–5.6  for  Ambrose’s  type  II lesions)
or  SACS  (P  < 0.001,  OR 8.71;  CI, 5.15–14.73  for complex  lesions  and  P < 0.001,  OR  5.99; CI,  3.66–9.81  for
Ambrose’s  type  II lesions).
Conclusions:  Nearly  50%  of  patients  with  perioperative  ACS  have  evidence  of  coronary  plaque  rupture,
characterizing  a  type  1 myocardial  infarction.
© 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Annually, more than 230 million noncardiac surgeries are per-
formed worldwide [1].  Despite improvements in surgical and
anesthetic techniques, mortality and cost related to these proce-
dures are raising [2].  Cardiac complications are a major cause of
morbidity and mortality after noncardiac surgeries, and patients
experiencing a perioperative myocardial infarction (MI) have a high
mortality and prolonged hospital stay [3].
The etiology and pathophysiology of myocardial ischemia and
infarction after noncardiac surgery is still subject of controversies
[1,3–7].  In this setting, it may  involve thrombosis over a vulner-
able plaque or decreased oxygen supply secondary to anemia or
hypotension, designated type 1 and type 2 by the universal def-
inition of MI  [8,9]. Depending on the predominant mechanism,
∗ Corresponding author at: Av. Dr. Eneas de Carvalho Aguiar, 44 andar AB, São
Paulo 05403-000, SP, Brazil. Tel.: +55 11 26615376; fax: +55 11 26615535.
E-mail address: danielle.gualandro@incor.usp.br (D.M. Gualandro).
prognosis and treatment may  be different. Although two retrospec-
tive pathology studies reported that nearly 50% of patients with
fatal perioperative MI  have plaque disruption [10,11], it has been
suggested that, in patients who  survive a perioperative MI,  the inci-
dence of type 2 MI  would be much higher than type 1 [1].  However,
there are no studies designed to establish the pathophysiology in
patients that survived a perioperative acute coronary syndrome
(ACS).
The presence of coronary plaques with complex morphologic
features in coronary angiography is the angiographic hallmark
of unstable coronary syndromes and correlates with pathologic
plaque rupture and thrombus, characterizing a type 1 MI  [12–19].
Ambrose’s type II eccentric lesions are strongly associated to dis-
rupted plaques and their ﬁnding have 92% speciﬁcity [17–20].
In order to determine the pathophysiology of ACS complicating
noncardiac surgery we compared the presence of plaque rupture as
a marker of type 1 MI  in patients with ACS after noncardiac surgery
(PACS), patients in the emergency room with spontaneous ACS
(SACS), and patients with stable coronary artery disease (CAD). The
present study was  performed at the biggest University Hospital in
0021-9150/$ – see front matter ©  2012 Elsevier Ireland Ltd. All rights reserved.
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Brazil where, roughly, 40,000 non-cardiac surgeries are performed
annually.
2. Methods
Between February 2006 and June 2010 clinical and angiographic
data were prospectively recorded into a database for 120 con-
secutive patients that had PACS after noncardiac surgery, for 120
patients with SACS, and for 240 patients with stable CAD. The study
protocol was approved by the hospital’s ethics committee.
2.1. Inclusion criteria
Consecutive patients submitted to noncardiac surgery who  pre-
sented with ACS within 30 days after the procedure were included
in the PACS group. Patients with suspected perioperative ACS were
evaluated by a cardiologist and were included if they had unsta-
ble angina with electrocardiographic ischemic signs (ST segment
depression or T wave abnormalities) or MI,  deﬁned as follows:
detection of a typical rise and fall of biochemical markers of myocar-
dial necrosis (troponin) with at least one value above the 99th
percentile of the upper reference limit together with: ischemic
symptoms or development of pathological Q waves on the elec-
trocardiogram (ECG) or ECG changes indicative of ischemia (ST
segment elevation or depression) [21].
For the SACS group, patients that had arrived in the emergency
room on random days and met  the same criteria of ACS were
included at admission.
For the stable CAD group, patients that were submitted to elec-
tive coronary angiography on random days were included before
the procedure. Angiography was indicated by clinic’s physician
based on symptoms of stable angina or evidence of CAD on com-
plementary tests.
2.2. Exclusion criteria
Patients in the PACS and SACS group were excluded if coronary
angiography was not performed. Patients in the stable CAD group
were excluded if they had had an ACS diagnosis in the previous 2
months.
2.3. Clinical data
Clinical data such as age, gender, presence of diabetes, hyper-
tension, smoking status, history of prior MI,  stable angina, heart
failure, prior myocardial revascularization procedures, and cardio-
vascular medication use were collected for the three study groups.
Patients in the PACS and SACS groups were followed-up until hos-
pital discharge, and information about recurrent unstable angina
and myocardial infarction and death was obtained. The use of
antiplatelet and anticoagulant agents prescribed for ACS treatment
and bleeding episodes were also recorded. Bleeding episodes were
classiﬁed as major or minor based on TIMI’s criteria [22].
2.4. Angiographic analysis
All angiographies were analyzed by a single experienced
observer who was unaware of the patients’ clinical diagnosis.
The number and location of coronary lesions with obstructions
greater than 50% were recorded. Each lesion was classiﬁed based
on Ambrose’s classiﬁcation [17–19].  This classiﬁcation divides the
lesions into 4 types: concentric (symmetric and smooth narrow-
ing), type I eccentric (asymmetric stenosis with smooth borders
and a broad neck), type II eccentric (asymmetric stenosis in the
form of a convex intraluminal obstruction with a narrow neck due
to one or more overhanging edges or irregular or scalloped borders,
or both) and multiple irregularities (three or more serial, closely
spaced narrowing or severe diffuse irregularities within a vessel)
[17–19].
Lesions were also categorized as complex or not using a classiﬁ-
cation adapted from Goldstein et al. [12]. Lesions were considered
complex if they caused at least 50% stenosis and had one or more
of the following morphologic features:
- An intraluminal ﬁlling defect consistent with thrombus, deﬁned
as abrupt vessel cutoff with persistence of contrast, or an intra-
luminal ﬁlling defect in a vessel within or adjacent to a stenotic
region with surrounding homogeneous contrast opaciﬁcation;
- Plaque ulceration, deﬁned by the presence of contrast and hazy
contour beyond the vessel lumen;
- Plaque irregularity (haziness), deﬁned by irregular margins or
overhanging edges;
- Impaired ﬂow (TIMI ﬂow < 3, except lesions characteristic of
chronic total occlusion, identiﬁed as tapering lesions with multi-
ple ﬁne collaterals).
The presence of at least one Ambrose’s type II lesion or a complex
lesion per patient was compared between the three study groups.
2.5. Statistical analysis
Base-line demographic characteristics, clinical and angio-
graphic variables were compared between the three groups.
Frequencies and percentages are given for categorical variables.
These variables were compared by chi-square test when applica-
ble and otherwise by Fisher’s exact test. Numerical variables are
reported as means ± standard deviation (SD). For continuous vari-
ables, statistical comparisons were made with use of Student’s
t-test (normal distribution) or Mann–Whitney test (asymmetric
distribution). Post hoc analysis for continuous variables was made
by the Tukey-HSD (honest signiﬁcant difference) test. Multivariate
logistic regression analysis was  performed to access independent
clinical predictors for plaque rupture in patients from all three
groups. All clinical variables with a value of P < 0.25 in univariate
analysis were tested. Belonging to PACS or SACS group, pres-
ence of diabetes or anemia, age > 70 years old, and lack of use of
aspirin, betablocker and statins were included in the multivari-
able model to test association with complex lesions. Belonging to
PACS or SACS group, not having hypertension or history of prior
MI,  anemia, and lack of use of aspirin, betablocker, and statins
were included in the multivariable model to test association with
Ambrose’s type II lesions. Adjusted odds ratio (OR) is reported
with corresponding 95% conﬁdence intervals (CI). Model adequacy
was measured by Hosmer & Lemeshow’s goodness of ﬁt test. A
P value of less than 0.05 was  considered to indicate statistical
signiﬁcance. All analyses were performed using the SPSS 15.0 soft-
ware.
3. Results
One hundred seventy patients with suspected PACS were eval-
uated. Nine patients were not included because they did not have
ACS (eight had isolated troponin elevations and one had pulmonary
thromboembolism). Forty patients were excluded because coro-
nary angiography was not performed and one patient was  excluded
due to technical reasons in analyzing the angiography, leaving 120
patients that were included in the PACS group. In the SACS group,
145 patients were evaluated and 120 were included. Overall, 480
patients and 1470 lesions were analyzed.
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Table 1
Baseline characteristics.
PACS (n = 120) SACS (n = 120) CAD (n = 240) P
Male sex no. (%) 86 (71.7) 81 (67.5) 157 (65.7) 0.52
Age  (years; mean ± SD) 67.82 ± 10.02 64.53 ± 12.41 61.95 ± 9.72 <0.001*
History of
Diabetes mellitus, n (%) 51 (42.5) 42 (35) 106 (44.4) 0.23
Hypertension, n (%) 99 (82.5) 101 (84.2) 203 (84.9) 0.84
Prior  MI,  n (%) 22 (18.3) 50 (41.7) 84 (35.1) <0.001
Stable  angina, n (%) 20 (16.7) 19 (15.8) 197 (82.5) <0.001
Heart  failure, n (%) 18 (15) 7 (5.8) 59 (24.7) <0.001
Smoking status, n (%)
No 41 (34.2) 52 (43.3) 122 (51)
Current 27 (22.5) 26 (21.7) 30 (12.6) 0.01
Previous 52 (43.3) 42 (35) 87 (36.4)
Prior  revascularization procedure, n (%)
None 98 (81.7) 69 (57.5) 160 (66.9)
0.004
PTCA 11 (9.2) 26 (21.7) 45 (18.8)
CABG 10 (8.3) 17 (14.2) 24 (10)
PTCA and CABG 1 (8.0) 8 (6.7) 10 (4.2)
Hemoglobin (g/dL; mean ± SD) 12.48 ± 2.21 13.73 ± 1.72 14.08 ± 1.57 <0.001†
Cr (mg/dL; mean ± SD) 1.68 ± 1.93 1.2 ± 0.72 1.25 ± 1.43 0.43
PACS: Perioperative acute coronary syndrome; SACS: Spontaneous acute coronary syndrome; CAD: coronary artery disease; n: number; SD: standard deviation; PTCA:
percutaneous transluminal coronary angioplasty; CABG: coronary artery bypass grafting; Cr: creatinine.
* PACS vs. SACS (P = 0.04); PACS vs. stable CAD (P < 0.001); SACS vs. stable CAD (P = 0.08).
† PACS vs. SACS (P < 0.001); PACS vs. stable CAD (P < 0.001); SACS vs. stable CAD (P = 0.21).
Table 2
Medication at admission.
PACS (n = 120) SACS (n = 120) CAD (n = 240) P
Aspirin, n (%) 60 (50) 68 (56.7) 229 (95.8) <0.001
-Blockers, n (%) 47 (39.2) 60 (50) 195 (81.6) <0.001
Statin, n (%) 36 (30) 59 (49.2) 201 (84.1) <0.001
ACE  inhibitor, n (%) 58 (48.3) 53 (44.2) 160 (70.5) <0.001
PACS: perioperative acute coronary syndrome; SACS: spontaneous acute coronary syndrome; CAD: coronary artery disease; n: number; ACE: angiotensin-converting enzyme.
3.1. Baseline characteristics
Clinical and laboratory characteristics of the 480 patients and
medications at the time of admission are listed in Tables 1 and 2,
respectively. There were no differences between the three groups in
the prevalence of male gender, hypertension or diabetes. Patients
in PACS group were older and had lower hemoglobin levels than
patients in SACS or stable CAD groups. Patients in PACS group also
had less prior history of known CAD (history of MI  or prior myocar-
dial revascularization procedures) than patients of the other two
groups.
3.2. Clinical data and outcome
In PACS group, the mean time between the procedure and the
ACS was 2.2 ± 3.3 days and 71.7% of patients had an ACS within
the ﬁrst 72 h after surgery. Regarding the type of operation, 46
patients (38.3%) were submitted to vascular surgery, 25 (20.8%) to
general abdominal surgery, 12 (10%) to urologic surgery, 10 (8.3%)
to orthopedic surgery, 7 (5.8%) to head and neck surgery, 7 (5.8%)
to neurosurgery, 4 (3.3%) to kidney transplantation, and 9 (7.7%)
to other procedures. Regarding anesthesia, 67 (60.4%) patients
received general anesthesia, 20 (18%) regional anesthesia and 24
(21.6%) combined general plus regional anesthesia. Mean anesthe-
sia duration was 363 ± 212 min  (range from 60 to 1425 min). Only
48 (40.7%) patients presented with chest pain as the clinical man-
ifestation of ACS. As for ACS classiﬁcation, 19 (15.8%) patients had
unstable angina, 94 (78.3%) had non-ST elevation MI  and 7 (5.8%)
had ST elevation MI.  In SACS group, 19 (5.8%) patients had unstable
angina, 78 (65%) had non-ST elevation MI  and 23 (19.2%) had ST
elevation MI.  Patients in the PACS group had a longer time from the
Table 3
Acute coronary syndrome treatment medication.
Medication PACS, n (%) SACS, n (%) P
Aspirin 119 (99.2) 118 (98.3) 1.00
Clopidogrel 78 (65) 82 (70.1) 0.40
Heparin 104 (86.7) 120 (100) <0.001
Tiroﬁban 11 (9.2) 90 (75) <0.001
-Blockers 102 (85) 110 (91.7) 0.10
Statin 118 (98.3) 120 (100) 0.50
ACE  inhibitor 94 (78.3) 108 (90) 0.01
Dobutamine 23 (19.2) 3 (2.5) <0.001
PACS: perioperative acute coronary syndrome; SACS: spontaneous acute coronary
syndrome; CAD: coronary artery disease; ACE: angiotensin-converting enzyme; n:
number.
ACS to angiography than patients in the SACS group (5.5 ± 8 days
vs. 1.3 ± 1.4 days, respectively; P < 0.001)
During follow-up there was  no difference between the PACS
and SACS groups regarding recurrent angina (12.5% vs. 10%, respec-
tively; P = 0.54) or myocardial infarction (10% vs. 5%, respectively;
P = 0.14), but patients in PACS group were more frequently on
Killip’s Classiﬁcation III and IV than patients in SACS group (35%
vs.12.5%, respectively; P < 0.001), and had higher mortality (15% vs.
4.2%; P = 0.02).
The use of antiplatelet agents and anticoagulant therapy in both
groups are shown in Table 3. Eleven (9.2%) patients in the PACS
group had a bleeding episode (6 major bleeding, including 2 fatal,
and 5 minor bleeding) whereas 10 (8.3%) patients in the SACS
group presented with bleeding (6 major and 4 minor but none
fatal; P = 0.09). Interestingly, only 3 patients on the PACS group pre-
sented with bleeding from the operative site and 5 patients had
gastrointestinal bleeding despite the use of ulcer prophylaxis.
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Table 4
Angiographic characteristics.
PACS, n (%) SACS, n (%) Stable CAD, n (%) P
Complex lesion 68 (56.7) 95 (79.2) 76 (31.8) <0.001
Ambrose’s type II lesions 54 (45) 68 (56.7) 44 (16.4) <0.001
Thrombus 9 (7.5) 39 (32.5) 21 (8.8) <0.001
Ulceration 15 (12.5) 18 (15) 16 (6.7) 0.03
Haziness 45 (37.5) 54 (45) 39 (16.3) <0.001
TIMI  ﬂow < 3 27 (22.5) 61 (50.8) 48 (20.1) <0.001
PACS: perioperative acute coronary syndrome; SACS: spontaneous acute coronary syndrome; CAD: coronary artery disease; n: number; TIMI: thrombolysis in myocardial
infarction.
3.3. Angiographic results
Twenty-eight patients did not have obstructions above 50%: 7
(5.8%) in PACS group, 3 (2.5%) in SACS group and 18 (7.5%) in stable
CAD group. Of the 1471 lesions analyzed, 349 were in patients of
the PACS group (mean 2.86 ± 1.71 lesions per patient), 404 were in
patients of the SACS group (mean 3.31 ± 1.71 lesions per patient),
and 717 were in patients of the stable CAD group (mean 2.94 ± 1.86
lesions per patient; P = 0.10). There was no difference between the
three groups regarding the location of the lesions.
In PACS group, 45% of patients had Ambrose’s type II lesions vs.
56.7% in SACS group and 16.4% in stable CAD group (P < 0.001). Both
PACS and SACS patients had more complex lesions than patients in
stable CAD group (56.7% vs. 79.2% vs. 31.8%, respectively; P < 0.001).
Comparison between angiographic characteristics of patients is
shown in Table 4.
After univariate analysis, applied to the entire cohort of 480
patients, the following variables were associated to the presence
of complex lesions, and were included in the multivariable model:
belonging to PACS or SACS group (P < 0.001), presence of dia-
betes (P = 0.153), presence of anemia (P = 0.002), age > 70 years
old (P = 0.002), and lack of medication use: aspirin (P < 0.001),
betablocker (P < 0.001) and statins (P = 0.001). The independent pre-
dictors of complex lesions were being in the group PACS (P < 0.001;
OR, 2.86; 95% CI, 1.82–4.52) or SACS (P < 0.001; OR, 8.71; 95% CI,
5.15–14.73) and the presence of diabetes (P = 0.025; OR, 1.58; 95%
CI, 1.06–2.36; Table 5). The variables associated to Ambrose’s type II
lesions in the univariate model, that were included in the multivari-
able model, were: belonging to PACS or SACS group (P < 0.001), not
having hypertension (P = 0.221) or history of prior MI  (P = 0.148),
anemia (P = 0.004), and lack of medication use: aspirin (P < 0.001),
betablocker (P = 0.004), and statins (P = 0.002). The independent
predictors of Ambrose’s type II lesions were being in the group PACS
(P < 0.001; OR, 3.43; 95% CI, 2.1–5.6) or SACS (P < 0.001; OR, 5.99;
95% CI, 3.66–9.81; Table 5).
4. Discussion
This was the ﬁrst prospective study that evaluated the pres-
ence of plaque rupture in consecutive patients with ACS after
Table 5
Independent predictors of plaque rupture in the multivariate logistic regression
model.
Adjusted OR 95% CI P
Predictors of complex lesions*
PACS group 2.86 1.82–4.52 <0.001
SACS group 8.71 5.15–14.73 <0.001
Diabetes 1.58 1.06–2.36 0.025
Predictors of Ambrose’s type II lesions†
PACS group 3.43 2.10–5.60 <0.001
SACS group 5.99 3.66–9.81 <0.001
PACS: perioperative acute coronary syndrome; SACS: spontaneous acute coronary
syndrome.
* Hosmer & Lemeshow goodness of ﬁt: P = 0.647.
† Hosmer & Lemeshow goodness of ﬁt: P = 0.270.
noncardiac surgery. Regarding the clinical and outcome charac-
teristics of patients with perioperative ACS, our study conﬁrmed
previous ﬁndings that perioperative ACS occurs mainly within the
ﬁrst 72 h of the procedure, most events are non ST-elevation MI  and
only 40% of patients have thoracic pain [5,6,23–26].  As expected, in-
hospital mortality was higher in patients with perioperative ACS
than spontaneous ACS. This ﬁnding could be attributed to base-
line diseases (co-morbidities) that motivated surgery (malignant
disease, vascular disease, trauma, etc.).
Our ﬁndings suggest that nearly 50% of patients with periopera-
tive ACS have markers of plaque disruption, suggesting a type 1 MI.
Our data is in line with the two retrospective autopsy studies that
investigated coronary anatomy in patients with fatal perioperative
MI.  Dawood et al. [10] studied 42 patients with fatal perioperative
MI  and found out that 55% of patients had evidence of unstable
plaques with disruption. Cohen et al. [11] also studied 26 patients
with fatal perioperative MI  and detected plaque rupture on autopsy
in 45% of them. In a retrospective study that used a catheterization
laboratory database, Berger et al. [27] identiﬁed 48 patients referred
for emergency coronary angiography for acute MI  within 7 days of
noncardiac surgery. Only critically ill patients with postoperative
MI  were included: 33 patients (68.8%) had ST-segment elevation,
and 21 patients had cardiogenic shock. Although the purpose of
their study was  to determine the clinical course and outcome of
patients undergoing immediate angiography for perioperative MI
and not to study the angiographic characteristics, they reported the
presence of thrombus in 30 patients (62.5%).
Differently from Berger et al. [27], Dawood et al. (28%) [10]
and Cohen et al. (35%) [11] we  found a low percentage of throm-
bus in angiography of patients in PACS group (7.5%). This result
may be related to the long time between MI  and angiography
in this group (5.5 days in average), consequently prolonged time
under antiplatelet and anticoagulant agents, spontaneous lysis of
some thrombi, and the small number of patients with ST-elevation
MI (more prone to exhibit thrombus over culprit lesion). Indeed,
patients with perioperative non-ST-elevation ACS usually are more
severely ill than patients with spontaneous SCA, and before being
referred to coronary angiography, physicians had to be sure that
the patient could receive antiplatelet and anticoagulant therapy
(considering the risk of bleeding) and that infections were under
control. Reinforcing the presence of unstable coronary plaques in
perioperative ACS, we  found similar frequencies of haziness and
ulceration on angiography in PACS and SACS groups, an unlikely
ﬁnding in patients with stable CAD. Indeed, multivariate analysis
indicated that belonging to PACS or SACS groups was associated
to an increased risk of angiographic markers of plaque disruption.
Out of the perioperative setting and using intravascular ultrasound,
Hong et al. also found that the only independent predictor of coro-
nary plaque disruption among patients with stable angina and
myocardial infarction was having the diagnosis of acute MI  [28].
Conversely, previous authors have suggested that postoperative
tachycardia, hypotension, hypertension, anemia, and hypoxemia
are common causes of prolonged ST-depression and type 2 infarc-
tion in patients with stable CAD undergoing noncardiac surgery
[1]. The cornerstone of this hypothesis is the ﬁnding of prolonged
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ST depression in perioperative Holter monitoring preceding the
ischemic event in previous studies [29]. In addition, the rare occur-
rence of ST elevation MI  in PACS reinforces the theory that the
incidence of type 2 MI  could be higher than type 1 MI  [1,29].  In spite
of its theoretical biological plausability, until now there was no clin-
ical evidence about the true incidence of type 1 MI.  The present
study provided this missing evidence.
Our study has some limitations. Among the excluded patients,
18 (45%) died before the angiography could be done, reﬂecting their
critical clinical status, and we missed their angiographic character-
istics. We  used coronary angiography for classifying lesions and
determine the presence of plaque disruption. Although it is not the
gold standard to diagnose plaque rupture, previous authors showed
that complex angiographic lesion morphology and Ambrose’s type
II lesions are strongly correlated with plaque rupture [20,16].
In conclusion, nearly 50% of patients with perioperative
myocardial infarction have evidence of coronary plaque rupture,
characterizing a type 1 MI.
5. Clinical implications
The present study indicates that, as well as in spontaneous ACS,
plaque rupture plays an important role in the pathophysiology of
perioperative ACS. At the bed side, this information is very useful,
as antiplatelet and anticoagulant therapies and invasive evaluation
should be strongly considered. On the other hand, type 1 and type
2 MI  mechanism are not mutually exclusive in the pathophysiol-
ogy of perioperative ACS. In consequence, preventing hypotension,
tachycardia, anemia and hypertension remain important in the
care of patients with perioperative ACS. Therefore, prevention and
treatment measures that act in both mechanisms are essential for
reducing the occurrence and mortality of perioperative ACS.
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